Annals of Surgical Oncology

, Volume 18, Issue 1, pp 65–71

Update on DCIS Outcomes from the American Society of Breast Surgeons Accelerated Partial Breast Irradiation Registry Trial

Authors

    • Department of SurgeryNorthwestern University Feinberg School of Medicine
  • Henry M. Kuerer
    • Department of Surgical OncologyUniversity of Texas M. D. Anderson Cancer Center
  • Peter D. Beitsch
    • Department of SurgeryDallas Breast Center
  • Frank A. Vicini
    • Department of Radiation OncologyWilliam Beaumont Hospital
  • Martin Keisch
    • Radiation OncologyAventura Comprehensive Cancer Center
Breast Oncology

DOI: 10.1245/s10434-010-1192-z

Cite this article as:
Jeruss, J.S., Kuerer, H.M., Beitsch, P.D. et al. Ann Surg Oncol (2011) 18: 65. doi:10.1245/s10434-010-1192-z

Abstract

Background

Since the initial reports on use of MammoSite accelerated partial breast irradiation (APBI) for treatment of ductal carcinoma in situ (DCIS), additional follow-up data were collected. We hypothesized that APBI delivered via MammoSite would continue to be well tolerated, associated with a good cosmetic outcome, and carry a low risk for recurrence in patients with DCIS.

Materials and Methods

From 2002–2004, 194 patients with DCIS were enrolled in a registry trial to assess the MammoSite. Follow-up data were available for all 194 patients. Median follow-up was 54.4 months; 63 patients had at least 5 years of follow-up. Data obtained included patient-, tumor-, and treatment-related factors, and recurrence incidence.

Results

Of the 194 patients, 87 (45%) had the MammoSite placed at lumpectomy; 107 patients (55%) had the device placed postlumpectomy. In the first year of follow-up, 16 patients developed a breast infection, though the method of device placement was not associated with infection risk. Also, 46 patients developed a seroma that was associated with applicator placement at the time of lumpectomy (P = 0.001). For patients with at least 5 years of follow-up, 92% had favorable cosmetic results. There were 6 patients (3.1%) who had an ipsilateral breast recurrence, with 1 (0.5%) experiencing recurrence in the breast and axilla, for a 5-year actuarial local recurrence rate of 3.39%.

Conclusions

During an extended follow-up period, APBI delivered via MammoSite continued to be well tolerated for patients with DCIS. Use of this device may make lumpectomy possible for patients who would otherwise choose mastectomy because of barriers associated with standard radiation therapy.

Copyright information

© Society of Surgical Oncology 2010